SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881106059693v1
0269881106059693v2
20/4/536    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sachs, G.
Right arrow Articles by Iwamoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sachs, G.
Right arrow Articles by Iwamoto, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Bipolar Disorder
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

Gary Sachs

Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

Raymond Sanchez

Ronald Marcus

Elyse Stock

Bristol-Myers Squibb Company, Wallingford, CT, USA

Robert Mcquade

William Carson

Otsuka America Pharmaceutical Inc., Princeton, NJ, USA

Neveen Abou-Gharbia

Bristol Myers Squibb Company, Lawrenceville, Princeton, NJ, USA

Cheryl Impellizzeri

Stephen Kaplita

Linda Rollin

Bristol-Myers Squibb Company, Wallingford, CT, USA

Taro Iwamoto

Otsuka Pharmaceutical Co. Ltd, Chiyoda-ku, Tokyo, Japan

This study compares the efficacy, safety, and tolerability of a partial dopamine agonist, aripiprazole, with placebo in the treatment of patients with bipolar I disorder experiencing an acute manic or mixed episode. In total, 272 hospitalized patients were randomized to aripiprazole 30mg/day or placebo in this 3-week, double-blind, placebo-controlled trial. Dosing could be reduced to 15mg/day for tolerability and, subsequently, increased to 30mg/day based on clinical response. Primary efficacy measure was mean change from baseline to endpoint in Young Mania Rating Scale (YMRS) total score; response was defined as 50% decrease from baseline YMRS score. Aripiprazole-treated patients demonstrated significantly greater improvement from baseline to endpoint in mean YMRS total scores compared with placebo-treated patients as early as Day 4 and sustained through Week 3. A significantly higher response rate was observed in aripiprazole-treated patients (53% vs. 32% at endpoint). Aripiprazole produced significantly greater improvements from baseline on other efficacy assessments compared with placebo, including Clinical Global Impression – Bipolar Version Severity and Improvement scores. The 30mg/day dose was maintained by 85% of aripiprazole-treated patients. Incidence of discontinuations due to adverse events was similar for aripiprazole (8.8%) and placebo (7.5%). Aripiprazole treatment resulted in no significant difference from placebo in change in mean body weight and was not associated with elevated serum prolactin or QTc prolongation. In conclusion, aripiprazole demonstrated superior efficacy to placebo in the treatment of patients with bipolar I disorder presenting with acute manic or mixed episodes, and exhibited a favourable safety and tolerability profile.

Key Words: aripiprazole • bipolar I disorder • efficacy • safety

This version was published on July 1, 2006

Journal of Psychopharmacology, Vol. 20, No. 4, 536-546 (2006)
DOI: 10.1177/0269881106059693


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
K. Aitchison, M Bienroth, J Cookson, R Gray, P. Haddad, B Moore, L Ratna, G Sullivan, D Taylor, M Taylor, et al.
A UK consensus on the administration of aripiprazole for the treatment of mania
J Psychopharmacol, May 1, 2009; 23(3): 231 - 240.
[Abstract] [PDF]


Home page
Br. J. PsychiatryHome page
A. H. Young, D. A. Oren, A. Lowy, R. D. McQuade, R. N. Marcus, W. H. Carson, N. H. Spiller, A. F. Torbeyns, and R. Sanchez
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
The British Journal of Psychiatry, January 1, 2009; 194(1): 40 - 48.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
E. Vieta, C. T'joen, R. D. McQuade, W. H. Carson Jr., R. N. Marcus, R. Sanchez, R. Owen, and L. Nameche
Efficacy of Adjunctive Aripiprazole to Either Valproate or Lithium in Bipolar Mania Patients Partially Nonresponsive to Valproate/Lithium Monotherapy: A Placebo-Controlled Study
Am J Psychiatry, October 1, 2008; 165(10): 1316 - 1325.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
P. Shajahan, A. MacRae, M. Bashir, and M. Taylor
Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy
J Psychopharmacol, September 1, 2008; 22(7): 778 - 783.
[Abstract] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
J. Cookson
Atypical antipsychotics in bipolar disorder: the treatment of mania
Adv. Psychiatr. Treat., September 1, 2008; 14(5): 330 - 338.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
H. Scherk, F. G. Pajonk, and S. Leucht
Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Arch Gen Psychiatry, April 1, 2007; 64(4): 442 - 455.
[Abstract] [Full Text] [PDF]



Advertisement